Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy EyePoint Pharmaceuticals stock | $11.52

Learn how to easily invest in EyePoint Pharmaceuticals stock.

EyePoint Pharmaceuticals Inc is a biotechnology business based in the US. EyePoint Pharmaceuticals shares (EYPT) are listed on the NASDAQ and all prices are listed in US Dollars. EyePoint Pharmaceuticals employs 98 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in EyePoint Pharmaceuticals

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – EYPT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

EyePoint Pharmaceuticals stock price (NASDAQ: EYPT)

Use our graph to track the performance of EYPT stocks over time.

EyePoint Pharmaceuticals shares at a glance

Information last updated 2021-10-25.
Latest market close$11.52
52-week range$3.51 - $15.06
50-day moving average $10.82
200-day moving average $9.71
Wall St. target price$21.20
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.06

Buy EyePoint Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy EyePoint Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

EyePoint Pharmaceuticals price performance over time

Historical closes compared with the close of $11.52 from 2021-10-25

1 week (2021-10-19) -3.44%
1 month (2021-09-24) -1.71%
3 months (2021-07-26) 44.72%
6 months (2021-04-26) 11.95%
1 year (2020-10-26) 2,706.33%
2 years (2019-10-25) 423.64%
3 years (2018-10-26) 418.92%
5 years (2016-10-26) 430.88%

EyePoint Pharmaceuticals financials

Revenue TTM $39.2 million
Gross profit TTM $11.2 million
Return on assets TTM -18.12%
Return on equity TTM -74.85%
Profit margin -106.12%
Book value $3.72
Market capitalisation $345.5 million

TTM: trailing 12 months

Shorting EyePoint Pharmaceuticals shares

There are currently 1.4 million EyePoint Pharmaceuticals shares held short by investors – that's known as EyePoint Pharmaceuticals's "short interest". This figure is 3.7% down from 1.4 million last month.

There are a few different ways that this level of interest in shorting EyePoint Pharmaceuticals shares can be evaluated.

EyePoint Pharmaceuticals's "short interest ratio" (SIR)

EyePoint Pharmaceuticals's "short interest ratio" (SIR) is the quantity of EyePoint Pharmaceuticals shares currently shorted divided by the average quantity of EyePoint Pharmaceuticals shares traded daily (recently around 117600). EyePoint Pharmaceuticals's SIR currently stands at 11.64. In other words for every 100,000 EyePoint Pharmaceuticals shares traded daily on the market, roughly 11640 shares are currently held short.

However EyePoint Pharmaceuticals's short interest can also be evaluated against the total number of EyePoint Pharmaceuticals shares, or, against the total number of tradable EyePoint Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case EyePoint Pharmaceuticals's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 EyePoint Pharmaceuticals shares in existence, roughly 50 shares are currently held short) or 0.0639% of the tradable shares (for every 100,000 tradable EyePoint Pharmaceuticals shares, roughly 64 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against EyePoint Pharmaceuticals.

Find out more about how you can short EyePoint Pharmaceuticals stock.

EyePoint Pharmaceuticals share dividends

We're not expecting EyePoint Pharmaceuticals to pay a dividend over the next 12 months.

Have EyePoint Pharmaceuticals's shares ever split?

EyePoint Pharmaceuticals's shares were split on a 1:10 basis on 8 December 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your EyePoint Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for EyePoint Pharmaceuticals shares which in turn could have impacted EyePoint Pharmaceuticals's share price.

EyePoint Pharmaceuticals share price volatility

Over the last 12 months, EyePoint Pharmaceuticals's shares have ranged in value from as little as $3.511 up to $15.06. A popular way to gauge a stock's volatility is its "beta".

EYPT.US volatility(beta: 1.26)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while EyePoint Pharmaceuticals's is 1.255. This would suggest that EyePoint Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

EyePoint Pharmaceuticals overview

EyePoint Pharmaceuticals, Inc. , a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor that is in Phase 1 clinical trials for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc. , Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc.

Frequently asked questions

What percentage of EyePoint Pharmaceuticals is owned by insiders or institutions?
Currently 12.584% of EyePoint Pharmaceuticals shares are held by insiders and 74.757% by institutions.
How many people work for EyePoint Pharmaceuticals?
Latest data suggests 98 work at EyePoint Pharmaceuticals.
When does the fiscal year end for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals's fiscal year ends in December.
Where is EyePoint Pharmaceuticals based?
EyePoint Pharmaceuticals's address is: 480 Pleasant Street, Watertown, MA, United States, 02472
What is EyePoint Pharmaceuticals's ISIN number?
EyePoint Pharmaceuticals's international securities identification number is: US30233G2093
What is EyePoint Pharmaceuticals's CUSIP number?
EyePoint Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 30233G100

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site